登录

Hyperway Secures ¥10 Million in Series A Funding

作者: Mailman 2021-04-22 15:21
海博为
http://hyperwaypharma.com
企业数据由 动脉橙 提供支持
创新药、高端仿制药研发商 | B轮 | 运营中
中国-四川
2023-08-08
策源资本
查看

(VCBeat) Apr. 14, 2021 -- Chengdu Hyperway Pharmaceuticals Co., Ltd. ("Hyperway"), a company focusing on the R&D of innovative drugs, has recently closed tens of millions of yuan in Series A funding. So far, Hyperway has raised three rounds of financing, with a total of over 100 million yuan.


The latest round was jointly led by Huaige Capital and Sichuan Academician Science and Technology Innovation Fund ( "Sichuan Academician Fund") under the management of Sichuan Development Hongke Investment. Proceeds from this transaction will be used for the development of Hyperway's multiple first-in-class drug candidates as well as four IND applications that will be completed this year and next.


Hyperway is a startup biotech company founded in January 2019 by a group of high caliper biotech entrepreneurs and industry veterans, located in Chengdu high tech Development Zone. Hyperway is committed to discover and develop new medicines to address unmet medical needs using breakthroughs in science and technology.


Hyperway has attracted many talents worldwide in building a world-class R&D team and scientific advisory team. Its core team members have many years of scientific and management experience in leading global or domestic pharmaceutical companies, such as Bayer, Sanofi, Merck, Wuxi PharmaTech, ChemPartner and Amgen. Among their achievements, some are inventors of several first-in-class new drug candidates that are being evaluated in clinical trials. 


Within a short period of time, Hyperway has developed an impressive pipeline cover many therapeutic areas, including oncology, pain, and CNS (central nervous system). Among them, one of the core products, HBW-3-10, as a second-generation BTK inhibitor, can overcome the severe resistance of the first-generation BTK inhibitors represented by ibrutinib and will complete the IND application this year.


>>>>

About Huaige Capital


Founded in 2016, Huaige Capital is a Shanghai-headquartered venture capital focusing on the healthcare sector (medical devices, innovative drugs, biologics, outsourcing services, etc.), and preferably invest at the early or growth stage. In line with the spirit of "integration and specialization", the company is committed to creating greater value for both its investors and its portfolio companies.


>>>>

About Sichuan Academician Fund


Sichuan Academician Fund was initiated and established by Sichuan Development Holding, with an initial scale of 1 billion yuan. It is a theme fund that accurately serves high-level talents, aiming to better promote the application of high-level scientific and technological innovation achievements in Sichuan. Sichuan Development Holding is one of the few trillion-dollar state-owned enterprises in the western region and even the whole country.

相关赛道 生物制药
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

【首发】上海生物医药基金投资美国生物治疗公司Geneos,助推个性化治疗癌症疫苗步入临床

【首发】友芝友生物完成2亿元Pre-C轮融资,加速双特异抗体和新冠疫苗产品临床研发

【首发】复诺健获投逾1.2亿美元D2轮融资,进一步奠定行业领先地位

【首发】翌圣生物完成近3亿元B+轮融资,持续加大分子酶及相关生命科学产业领域投入

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

EndoVas Medical Raises ¥10M in Additional Series Pre-A Funding

2021-04-22
下一篇

EDDA Technology Secures $150 Million in New Financing Round

2021-04-22